| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/04/2006 | US7022821 Tumor Antigen Derived Gene-15 (TADG-15); a detectably labeled antibody specific for the TADG-15 protein which has a molecular size of 100 kDa and comprises CUB, LDLR and serine protease domains; useful in the diagnosis or treatment of breast and ovarian cancer in particular |
| 04/04/2006 | US7022820 Nucleotide sequences for use in the treatment and detection of tumor disorders |
| 04/04/2006 | US7022818 of given amino acid sequence; use as a target for drug screening of antagonists or agonists of said receptor; receptor can bind persephin |
| 04/04/2006 | US7022673 Generation of biocompatible active macromolecules with amplified half-life; obtain macromolecule, couple to polymer, recover macromolecule |
| 04/04/2006 | US7022663 Comprising as active ingredient a therapeutically effective amount of Copolymer 1 (glatiramer acetate), and microcrystalline cellulose; treatment of autoimmune diseases |
| 04/04/2006 | US7022525 Process of making a compound by forming a polymer from a template drug |
| 04/04/2006 | US7022511 Process for the isolation and acclimatization of bacteria for lignin degradation |
| 04/04/2006 | US7022500 Humanized immunoglobulins |
| 04/04/2006 | US7022492 Ecstasy haptens and immunogens |
| 04/04/2006 | US7022484 Methods for treating neuropathological states and neurogenic inflammatory states and methods for identifying compounds useful therein |
| 04/04/2006 | US7022482 Deactivation antigen protein; anticancer agents; Aids therapy |
| 04/04/2006 | US7022328 Therapeutic and diagnostic compositions |
| 04/04/2006 | US7022327 Recombinant birnavirus vaccine |
| 04/04/2006 | US7022326 Carboxymethylated retroviral regulatory proteins and interferon-α |
| 04/04/2006 | US7022325 Decapeptide immunogen able inducing cytotoxic lymphocytes, is used to provide a protection against an HIV infection; biodrugs |
| 04/04/2006 | US7022324 Stabilized viral envelope proteins and uses thereof |
| 04/04/2006 | US7022323 Prevent infections using envelope glycoprotein; binding to antibody |
| 04/04/2006 | US7022322 Comprises ligand for human immunoglobulin for immunoapheresis, which mimicks sequence of an adrenergic receptor structure |
| 04/04/2006 | US7022320 Eliciting an immune response by administering a vector construct which comprising a recombinant polynucleotide, able encoding a Mycobacterium tuberculosis antigen in human; administering antigen protein, or live attenuated vaccine; gold core carrier; dna vaccines |
| 04/04/2006 | US7022319 Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy |
| 04/04/2006 | US7022313 Hydrogel particle formulation |
| 04/04/2006 | US7022309 Targeting molecule linked to an imaging agent |
| 04/04/2006 | CA2187207C Poxvirus-canine distemper virus (cdv) recombinants and compositions and methods employing the recombinants |
| 04/04/2006 | CA2120503C The regulation of systemic immune responses utilizing cytokines and antigens |
| 04/04/2006 | CA2116138C Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| 03/30/2006 | WO2006034507A2 Methods of diagnosing and treating complications of pregnancy |
| 03/30/2006 | WO2006034395A2 Methods and compositions relating to mannuronic acid specific binding peptides |
| 03/30/2006 | WO2006034320A2 Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine |
| 03/30/2006 | WO2006034292A2 Antibodies against and methods for producing vaccines for respiratory syncytial virus |
| 03/30/2006 | WO2006034207A2 Use of gsk3 inhibitors in combination with radiation therapies |
| 03/30/2006 | WO2006033995A2 Thiazolidin-4-ones having anti-hepatitis b activity |
| 03/30/2006 | WO2006033918A2 Polypeptides for inducing a protective immune response against staphylococcus aureus |
| 03/30/2006 | WO2006033702A2 Anti-cd154 antibodies |
| 03/30/2006 | WO2006033675A2 Bacillus anthracis spore specific antobodies |
| 03/30/2006 | WO2006033672A2 Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
| 03/30/2006 | WO2006033665A1 Tat-based vaccine compositions and methods of making and using same |
| 03/30/2006 | WO2006033386A1 STABILIZED HUMAN IgG4 ANTIBODIES |
| 03/30/2006 | WO2006032674A1 Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| 03/30/2006 | WO2006032533A1 Novel vaccine for veterinary and human medicine prophylaxis and therapy |
| 03/30/2006 | WO2006032525A2 Combinational therapy for treating cancer |
| 03/30/2006 | WO2006032499A1 Purification process for bacterial cytolysin |
| 03/30/2006 | WO2006032330A1 Annexin modulation and resistance to infection |
| 03/30/2006 | WO2006032245A1 Pharmaceutical active ingredient against hiv - syndrome |
| 03/30/2006 | WO2006020581A9 Prevention and treatment of synucleinopathic and amyloidogenic disease |
| 03/30/2006 | WO2006017749A3 Optimizing expression of active botulinum toxin type a |
| 03/30/2006 | WO2006014965A9 Pharmaceutical formulation and process |
| 03/30/2006 | WO2006008076A8 Methods and agents stimulating the immune response |
| 03/30/2006 | WO2006000920A3 Dimensional analysis of saccharide conjugates with gpc & sec-mals |
| 03/30/2006 | WO2005121169A3 Apoptosis-inducing polypeptides |
| 03/30/2006 | WO2005120567A3 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof |
| 03/30/2006 | WO2005118643A3 Antibodies to angiogenesis inhibiting domains of cd148 |
| 03/30/2006 | WO2005117973A3 Bispecific binding agents for modulating biological activity |
| 03/30/2006 | WO2005115458A3 Methods and compositions related to regulation of nucleo-cytoplasmic localization of e1 dna helicase in papillomaviruses |
| 03/30/2006 | WO2005112991A3 Vaccines |
| 03/30/2006 | WO2005111065A3 Epitope-enhancement of a human cd4 hiv epitope |
| 03/30/2006 | WO2005109991A3 Anti-theileriosis vaccine |
| 03/30/2006 | WO2005107802A3 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients |
| 03/30/2006 | WO2005106009A3 Lactoferrin cleavage of neisserial proteins |
| 03/30/2006 | WO2005103710A3 Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 1 (crhr1) |
| 03/30/2006 | WO2005095460A3 Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof |
| 03/30/2006 | WO2005094877A3 Formulation of glutamic acid decarboxylase (gad65) and serum albumin |
| 03/30/2006 | WO2005071093A3 Chimpanzee adenovirus vaccine carriers |
| 03/30/2006 | WO2005068638A3 Promoter |
| 03/30/2006 | WO2005048935A3 Methods of modulating immunity |
| 03/30/2006 | WO2005013898A3 Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax |
| 03/30/2006 | WO2005013896A3 Programmed immune responses using a vaccination node |
| 03/30/2006 | WO2004070012A3 Cell-killing molecules and methods of use thereof |
| 03/30/2006 | WO2003014294A3 Tacis and br3 polypeptides and uses thereof |
| 03/30/2006 | US20060069242 Neurotrophic factor receptor |
| 03/30/2006 | US20060069239 Epididymis-specific gene as potential contraceptive target |
| 03/30/2006 | US20060069238 Synthetic glyco-lipo-peptides as vaccines |
| 03/30/2006 | US20060069054 Compositions and methods for the therapy and diagnosis of breast cancer |
| 03/30/2006 | US20060069035 Peptide for regulation of urokinase plasminogen activator and method of optimizing therapeutic efficacy |
| 03/30/2006 | US20060069025 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068495 Process of cell electrofusion |
| 03/30/2006 | US20060068453 Survivin, a protein that inhibits cellular apoptosis, and its modulation |
| 03/30/2006 | US20060068448 isolated nucleic acid encoding a fungal antigen from Candida albicans; antiallergenic reaction to fungi in a vertebrate; and diagnosing a disease caused by fungi in a vertebrate; desensitization therapy for vaccines; immunosuppressants; insoluble cytoplasmic membrane proteins, free of cell wall |
| 03/30/2006 | US20060068386 Complete genome and protein sequence of the hyperthermophile methanopyrus kandleri av19 and monophyly of archael methanogens and methods of use thereof |
| 03/30/2006 | US20060067951 Signal peptides, nucleic acid molecules and methods for treatment of caries |
| 03/30/2006 | US20060067950 Clostridial neurotoxins for use in wound healing |
| 03/30/2006 | US20060067949 Immunization with porphyromonas gingivalis protects against heart disease |
| 03/30/2006 | US20060067948 Viral vectors |
| 03/30/2006 | US20060067946 Method of treatment using ligand-immunogen conjugates |
| 03/30/2006 | US20060067945 Production of recombinant protein pap 31 for the diagnosis and prevention of Bartonella bacilliformis infection |
| 03/30/2006 | US20060067944 Stable immunogenic product comprising antigenic heterocomplexes |
| 03/30/2006 | US20060067943 Stabilization of alum-adjuvanted immunologically active agents |
| 03/30/2006 | US20060067942 Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals |
| 03/30/2006 | US20060067941 Nanotubes for cancer therapy and diagnostics |
| 03/30/2006 | US20060067940 Monoclonal antibody or an antigen binding fragment that specifically binds amino acids of a West Nile virus E protein |
| 03/30/2006 | US20060067939 use of boron nitride nanostructures encapsulated with a biopolymer in boron neutron capture therapy; administering BN nanostructure-antibody composite species to a cancer patient such that composite species selectively target a tumor within such mammal, activating boron in the boron nitride composite |
| 03/30/2006 | US20060067938 Methods for the treatment of osteoarthritis and compositions thereof |
| 03/30/2006 | US20060067937 Methods of diagnosing and treating complications of pregnancy |
| 03/30/2006 | US20060067936 IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses |
| 03/30/2006 | US20060067935 Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
| 03/30/2006 | US20060067934 DNA sequences encoding tumor necrosis factor receptors; recombinant expression vectors |
| 03/30/2006 | US20060067933 Soluble receptor BR43x2 and methods of using |
| 03/30/2006 | US20060067932 Antagonists specific for denatured collagen and methods of using same |
| 03/30/2006 | US20060067931 Receptor for lysophosphatidylcholine in vascular endothelial cells and use thereof |
| 03/30/2006 | US20060067930 Polypeptide variants with altered effector function |
| 03/30/2006 | US20060067929 Administering a modified Clostridial toxin with a proteolytic domain; a translocation domain and an orphanin targeting moiety; the HC domain is removed or modified to reduce the targeting of the modified Clostridial toxin to the neuromuscular junction. |